Learning Objectives

  • Summarize the findings from cardiovascular outcomes studies of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)
  • Identify specific patient populations that would benefit from low-density lipoprotein cholesterol (LDL-C) lowering utilizing PCSK9i therapies
  • Apply the guidance from the latest clinical recommendations for the use of PCSK9i
  • Implement strategies to overcome common obstacles and potential solutions to increase patient access to PCSK9i